PMC4 A FRAMEWORK FOR DEVELOPING A FLEXIBLE CONTROL-BASED ASTHMA POLICY MODEL
Campbell JD p J 1 , Hansen RN 1 , Briggs A 2 , Sullivan SD 1 1 University of Washington, Seattle, WA, USA, 2 University of Glasgow, Glasgow, UK OBJECTIVES: The goal of asthma management is to gain and maintain control. Several validated patient-reported measures are available to assess the degree of control: Asthma Control Questionnaire (ACQ), Asthma Control Test (ACT), and the Asthma Therapy and Assessment Questionnaire (ATAQ). We propose a fl exible and transparent model structure that represents disease variability through exacerbation rates and any one of the three control instruments. METHODS: We developed a Markov model to simulate cohorts transitioning among six health states: an asthma control continuum state (variability in control is tracked using one of the three control instruments), three severity levels of asthma exacerbation, and asthma and non-asthma related death. To estimate the cost and outcome weights for the control continuum state, we explored the relationship between the ATAQ (higher ATAQ less control) and management costs (including absenteeism costs) and utilities using a large asthma registry of exacerbation-free patients. A hypothetical asthma intervention added to standard-of-care was compared to standard-of-care alone as summarized by the following product profi le: a 50% reduction in asthma exacerbation rates, a 0.5 absolute improvement in the ATAQ score, and an additional $10,000 per annum intervention cost. RESULTS: The estimated change in bi-weekly asthma management costs for a one unit increase in the ATAQ score was $36.12 (robust SE $3.95) and for utilities was 0.05 (robust SE 0.0041). Assuming a fi ve year time horizon, the hypothetical intervention plus standard-of-care had an incremental mean cost of $25,800 (95% interval $10,600, $41,000), quality adjusted life year (QALY) of 0.257 (0.106, 0.435), and cost per QALY of $100,500/QALY ($13,700, $199,800) . CONCLUSIONS: As relationships emerge between any of the instruments of control and costs and utilities, this versatile model can forecast: long-term burden of disease, value of existing and emerging interventions, and inputs that yield the highest return from further study.
PMC5 PRO AND UTILITY ASSESSMENT: ADDRESSING CONFOUNDS OF CHANGING SELF-REFERENCE Pashko S
Omnicare Clinical Research, King of Prussia, PA, USA Identity, the view of self-reference, is not static across populations and is probably not stable within an individual over time. Philosophers, psychologists and the religious continue to offer support for particular points of view of identity but there are many differences among them. These differences seem quite able to bias utility and patientreported outcomes assessments. As such, care must be taken to understand the selfreference schemas of the population within which self-assessments are validated and used. Some of the options people have and use for self-reference are: 1. operational (e.g., I am a clinical researcher or a father), 2. preference-oriented (e.g., I am a lover of wine or a "runner"), 3. physical (e.g., I am my body), 4. psychological (e.g., I am my ego), 5. religious (e.g., I am spirit) and 6. philosophical (e.g., I am thinking, I am consciousness, no such thing as identity exists, I am subjective experience). It's surprising self-assessments are conducted when we don't know who is responding to our questions. The confound of identity is important to study in its own right because of how strongly it can infl uence public policy through research fi ndings based on selfassessments. "View of self-reference" seems a fundamental and necessary element for inclusion into requirements for construction and validation of PROs. Otherwise, instrument bias could be specifi cally used to make a certain claim, much like regression towards the mean could be used if it was not previously identifi ed as a threat to validity. That identify may shift over time within an individual, say from an external focus to an internal focus, may be the reason why some terminally ill patients report good quality of life despite their poor health. When the body is not a factor in one's identity, what is the meaningfulness of health-related quality of life anyway?
PMC6

META-REGRESSION AS A METHOD OF IDENTIFICATION OF THE CAUSES OF HETEROGENEITY BETWEEN STUDIES ON THE EXAMPLE OF RELATIONSHIP BETWEEN SURROGATES AND CLINICALLY IMPORTANT ENDPOINTS IN TYPE-2 DIABETES MELLITUS
Marcisz A 1 , Rys P y 2 , Wieczorek A 1 , Plisko R 2 , Wladysiuk M 1 , Skrzekowska-Baran I 3 1 HTA Consulting, Krakow, Malopolska, Poland, 2 HTA Consulting, Krakow, Poland, 3 Novo Nordisk, Inc., Warsaw, Mazowieckie, Poland OBJECTIVES: Use of meta-regression to explain heterogeneity between the studies evaluating relationship between the level of glycated hemoglobin (HbA1c) and the risk of development of retinopathy in patients with type 2 diabetes mellitus (DMT2). In meta-regression the results of the studies under consideration are treated as points to be analyzed by weighted regression. If the results obtained in a model without covariates indicate heterogeneity of studies, then inclusion of subsequent covariates into the model can make it possible to check if specifi c variables explain heterogeneity. The amount of heterogeneity may be expressed as between-study variance. If betweenstudy variance decreases after inclusion of a specifi c covariate into the model, it means that heterogeneity between the studies may be explained by that covariate.
METHODS:
The following covariates were considered: observation period, type of the study, sample size, HbA1c level, age, duration of DMT2, BMI, cholesterol level, arterial blood pressure. Due to a scarce number of studies available between-study variance was estimated using the REML method. The value of between-study variance evaluated using a meta-regression model for retinopathy in DMT2 without covariates was 0.4547. RESULTS: Inclusion of the difference between the intervention group and the control group with respect to the HbA1c level resulted in decrease to 0.1572. Therefore the covariate under consideration explains the heterogeneity in 65.4%. The obtained value of directional coeffi cient was statistically signifi cant and equal to 0.5824, which means that increase of difference between the groups with HbA1c level by 1 unit results in increase of the logarithm of relative risk by 0.5824, refl ecting increase the risk by 1.79 times. CONCLUSIONS: It was demonstrated using metaregression that the difference with respect to the HbA1c level is the cause of heterogeneity between the studies. Relative risk of development of retinopathy increases with increase of the difference in HbA1c level.
PMC7 EFFECTS OF HETEROGENEITY ON THE ESTIMATION AND COMPARISON OF MEDICATION ERROR RATES
de Moor C, Golembesky A PPD Inc, Morrisville, NC, USA OBJECTIVES: The clinical consequences and costs of medication errors (ME) have signifi cant implications on quality of care. A detailed understanding of the occurrence and patterns of MEs is critical to reducing ME rates and improving patient outcomes. However, ME rates are often estimated inaccurately. ME rates are typically heterogeneous with respect to hospitals and units within hospitals, because of differences in health care provider (HCP) experience and skill. Although this heterogeneity has important implications for the precision and power of ME analysis, it is seldom taken into account in the estimation of MEs. METHODS: To evaluate the effects of heterogeneity on the precision and power of estimated ME rates, we assumed three sources of heterogeneity: hospital, unit (or HCP) within hospital, and random error. We derived formulas representing the variances of the estimated ME rates and the variances of comparisons of ME rates, and graphically illustrated the effects of sample sizes and magnitude of heterogeneity on the variances. RESULTS: The heterogeneity associated with hospital and unit induces clustering of MEs within hospitals and units, increasing variability in the estimated ME rates compared with what would be observed in the absence of heterogeneity. Even in the presence of low levels of heterogeneity, the variances of the estimated ME rates can be substantially increased. Power associated with comparisons of ME rates also can be substantially affected with decreased power for comparisons between hospitals or units and increased power for comparisons within hospitals or units. CONCLUSIONS: Heterogeneity of MEs with respect to hospitals and hospital units (or HCPs) can have a substantial effect on precision and power, and should be incorporated in the analyses ME rates. We provide precision and power formulas for planning future studies of MEs.
